Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PASSAGE BIO INC.
PASG | US
11.67
USD-0.01
-0.09%
PASG | US
Loading StockChartView...
About PASSAGE BIO INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
11.67
Open
11.65
High
12.00
Low
11.65
Passage Bio Inc. a genetic medicines company develops transformative therapies for central nervous system diseases. It develops PBGM01 a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02 a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03 a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement and a development services and clinical supply agreement with Catalent Maryland Inc. The company was incorporated in 2017 and is headquartered in Philadelphia Pennsylvania.
View LessPASG | US
Risk
147.9
Sharpe
0.44
Luna's Score
48/100
Recommendation
Hold
Luna says (PASG | US)
What's Working
Positive Momentum
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
153.5%1 month
147.9%3 months
112.7%6 months
123.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.41
Debt to equity
0.29
Debt to assets
0.21
Ent. to EBITDA
0.87
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-84.65M
MarketCap
720.82M
MarketCap(USD)
720.82M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-63.55
Short ratio
6.28
Short perc.
3.30
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
4.45
Range1M
6.09
Range3M
8.89
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.49
Price X volume
237.11K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.87 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.41 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 112.70 | 72.80 | Riskier |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.21 | 0.25 | Par |
| Market Cap | 720.82M | 3.66B | Emerging |
